5
5 things to know about the Pfizer/Allergan inversion collapse
April 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
